BBIO
BridgeBio Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$76.82
+3.77%Margins
Gross margin
93.5%
EBITDA margin
-46.6%
EBIT margin
-43.4%
Net margin
-60.3%
FCF margin
-39.6%
34.3%
Return on equity
-26.4%
Return on assets
-49.3%
Return on invested capital
0.56x
Asset turnover
-$369.0M
Cash from operations
$7.90
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Sep 1, 2026